The Impact of Exacerbation Frequency on Clinical and Economic Outcomes in Swedish COPD Patients: The ARCTIC Study

被引:9
|
作者
Larsson, Kjell [1 ]
Janson, Christer [2 ]
Lisspers, Karin [3 ]
Stallberg, Bjorn [3 ]
Johansson, Gunnar [3 ]
Gutzwiller, Florian S. [4 ]
Mezzi, Karen [4 ]
Bjerregaard, Bine Kjoeller [5 ]
Jorgensen, Leif [5 ]
机构
[1] Karolinska Inst, Natl Inst Environm Med, Integrat Toxicol, SE-17177 Stockholm, Sweden
[2] Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Uppsala, Sweden
[3] Uppsala Univ, Dept Publ Hlth & Caring Sci, Family Med & Prevent Med, Uppsala, Sweden
[4] Novartis Pharma AG, Global Patient Access, Basel, Switzerland
[5] IQVIA Solut, Real World Evidence Solut, Copenhagen, Denmark
关键词
chronic obstructive pulmonary disease; exacerbations; mortality; lung function; healthcare cost; Sweden; OBSTRUCTIVE PULMONARY-DISEASE; MANAGEMENT; DIAGNOSIS; MORTALITY; OVERLAP; DECLINE;
D O I
10.2147/COPD.S297943
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: The aim of this study was to assess the association between exacerbation frequency and clinical and economic outcomes in patients with COPD. Patients and Methods: Electronic medical record data linked to National Health Registries were collected from COPD patients at 52 Swedish primary care centers (2000-2014). The outcomes analyzed were exacerbation rate, mortality, COPD treatments, lung function and healthcare costs during the follow-up period. Based on the exacerbation rate two years before index date, the patients were initially classified into three groups, either 0, 1 or >= 2 exacerbations per year. After the index date, the classification into exacerbation groups was updated each year based on the exacerbation rate during the last year of follow-up. A sensitivity analysis was conducted excluding patients with asthma diagnosis from the analysis. Results: In total 18,586 COPD patients were analyzed. A majority of the patients (60-70%) who either have had no exacerbation or frequent exacerbations (>= 2/year) during the preindex period remained in their group (ie, with 0 or >= 2 annual exacerbations) during up to 11 years of follow-up. Compared with having no exacerbation, mortality was higher in patients having 1 (HR; 2.06 [1.93-2.201) and >= 2 (4.58 [4.33-4.841) exacerbations at any time during the follow-up. Lung function decline was more rapid in patients with frequent exacerbations and there was an almost linear relationship between exacerbations frequency and mortality. Total healthcare costs were higher in the frequent exacerbation group (>= 2/year) than in patients with no or one exacerbation annually (p<0.0001 for both). The results did not differ from the main analysis after exclusion of patients with a concurrent asthma diagnosis. Conclusion: In addition to faster lung function decline and increased mortality, frequent exacerbations in COPD patients imply a significant economic burden.
引用
收藏
页码:701 / 713
页数:13
相关论文
共 50 条
  • [1] Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study
    Larsson, Kjell
    Janson, Christer
    Stallberg, Bjorn
    Lisspers, Karin
    Olsson, Petter
    Kostikas, Konstantinos
    Gruenberger, Jean-Bernard
    Gutzwiller, Florian S.
    Uhde, Milica
    Jorgensen, Leif
    Johansson, Gunnar
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 995 - 1008
  • [2] Economic burden of COPD in a Swedish cohort: the ARCTIC study
    Lisspers, Karin
    Larsson, Kjell
    Johansson, Gunnar
    Janson, Christer
    Costa-Scharplatz, Madlaina
    Gruenberger, Jean-Bernard
    Uhde, Milica
    Jorgensen, Leif
    Gutzwiller, Florian S.
    Stallberg, Bjorn
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 275 - 285
  • [3] The economic burden of COPD in a Swedish cohort: The ARCTIC study
    Lisspers, Karin
    Larsson, Kjell
    Johansson, Gunnar
    Janson, Christer
    Costa-Scharplatz, Madlaina
    Gruenberger, Jean-Bernard
    Uhde, Milica
    Jorgensen, Leif
    Sobocki, Patrik
    Stallberg, Bjorn
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [4] Clinical and economic factors associated with spirometry-diagnosed COPD in the Swedish ARCTIC study
    Johansson, Gunnar
    Larsson, Kjell
    Stallberg, Bjorn
    Lisspers, Karin
    Olsson, Petter
    Gruenberger, Jean-Bernard
    Jorgensen, Leif
    Sobocki, Patrik
    Janson, Christer
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [5] Impact of clinical pathway on clinical outcomes in the management of COPD exacerbation
    Ban, Andrea
    Ismail, Aniza
    Harun, Roslan
    Rahman, Azahirafairud Abdul
    Sulung, Saperi
    Mohamed, Aljunid Syed
    BMC PULMONARY MEDICINE, 2012, 12
  • [6] Impact of clinical pathway on clinical outcomes in the management of COPD exacerbation
    Andrea Ban
    Aniza Ismail
    Roslan Harun
    Azahirafairud Abdul Rahman
    Saperi Sulung
    Aljunid Syed Mohamed
    BMC Pulmonary Medicine, 12
  • [7] Gender and economic aspects of COPD in a Swedish cohort: The ARCTIC study
    Lisspers, Karin
    Larsson, Kjell
    Jansson, Christer
    Stallberg, Bjorn
    Tsiligianni, Ioanna
    Gutzwiller, Florian S.
    Mezzi, Karen
    Uhde, Milica
    Jorgensen, Leif
    Johansson, Gunnar
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [8] Comorbidities in Swedish COPD and non-COPD patients: ARCTIC study
    Stallberg, Bjorn
    Janson, Christer
    Larsson, Kjell
    Johansson, Gunnar
    Kostikas, Konstantinos
    Gruenberger, Jean-Bernard
    Jorgensen, Leif
    Sobocki, Patrick
    Lisspers, Karin
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [9] Acute exacerbation phenotypes of asthma and COPD: impact on clinical outcomes
    Ghanizada, Muzhda
    Jabarkhil, Ajmal
    Hansen, Susanne
    Dyhre-Petersen, Nanna
    Woehlk, Christian
    Sondergaard, Marianne Baastrup
    Lapperre, Therese
    Porsbjerg, Celeste
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [10] The Impact of Conjugated Pneumococcal Vaccine on Exacerbation Frequency in Patients with COPD
    Ondes, Zeynep
    Varol, Yelda
    Cirak, Ali Kadri
    Hakoglu, Burcin
    Tekgul, Serpil
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58